Published on 21 November 2021
Alzheimer’s is a progressive neurodegenerative disease that usually starts slowly and gradually worsens over time. It constitutes for over 65% of dementia cases and currently has no cure. This paper reviews the biomarkers for Alzheimer’s Disease (AD) and evaluates these biomarkers based on various pathologies they are associated with, using the International Working Group (IWG) criteria, sensitivity, specificity etc. This paper summarizes the existing biomarkers, critically compares them and highlights which biomarkers are most effective for clinical diagnosis. It also discusses some of the drawbacks associated with using some biomarkers, either alone or in combination with others.